In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US ...

Japan-based pharmaceutical company Kyowa said it is planning to buy land in the Helix Innovation Park in Sanford, North Carolina to build a manufacturing facility to support the production and supply ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

Pharma giant AstraZeneca announced $3.5 billion in US capital investment that will expand its biopharmaceutical researching and manufacturing footprint in the country by the end of 2026. According to ...

Indian pharmaceutical company Intas Pharmaceuticals signed a deal to acquire Udenyca, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications. Accord ...

Industry will see mid-teens grams/L of product within five years but downstream processes are the big ‘virgin territory’ for further productivity gains, says Avantor’s Ger Brophy. In the aftermath of ...

Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

Articles In Color Color reprints are printed on 70# enamel paper and can be reproduced in color or in black and white. Color articles reprinted in black and white will be charged black and white ...

As of its 2023 guidance on combination and boundary products, the Australian Therapeutic Goods Administration (TGA) has provided context around key regulated product categories: Combination products ...

Sanofi will build a €1 billion ($1.1 billion) mAb production facility in Vitry-sur-Seine, while it invests €100 million to bolster capacity at its Le Trait site in Normandy and invests €10 million at ...

Contract development and manufacturing organization (CDMO) Celltechna, a part of the Northway Group, has broken ground on a gene therapy center in Vilnius, Lithuania. The €50 million ($54 million) ...